GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

elsunersen   Click here for help

GtoPdb Ligand ID: 14130

Synonyms: PRAX-222 | PRAX222
Compound class: Nucleic acid
Comment: Elsunersen (PRAX-222) is a 20-mer anti-sense oligonucleotide that is designed to selectively decrease expression of the gene for the voltage-gated sodium channel Nav1.2 (SCN2A). This is proposed as a mechanism to treat early onset developmental and epileptic encephalopathy (DEE) [1-3], that is driven by gain-of-function mutations in SCN2A. We include the linear nucleotide sequence in this entry, without the chemical modifications that are included in the administered version of elsunersen. A full descriptor is d([2'-O-(2-methoxyethyl)](m5rC-sp-m5rC-rA-5rC-rG-rA)-5C-sp-A-sp-T-p-A-p-T-p-T-p-T-p-T-p-T-p-m5C-sp-[2'-O-(2-methoxyethyl)]m5rU-[2'-O-(2-methoxyethyl)]rA-sp-[2'-O-(2-methoxyethyl)]m5rC-sp-[2'-O-(2-methoxyethyl)]rA).
No information available.
Summary of Clinical Use Click here for help
Intrathecally administered elsunersen (PRAX-222) is being evaluated for safety and effecacy as a treatment for SCN2A-DEE. Elsunersen was granted FDA orphan drug designation in 2021 for this indication.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05737784 A Clinical Trial of PRAX-222 in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy Phase 1/Phase 2 Interventional Praxis Precision Medicines